

Pharmacy Prior Authorization Form Fax completed form to: 877.974.4411 toll free, or 616.942.8206 Commercial (Individual/Optimized) This form applies to: Commercial (Traditional) Medicaid ☐ **Urgent** (life threatening) ☐ **Non-Urgent** (standard review) This request is: Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function. Symdeko[®] (Tezacaftor /ivacaftor) Member First Name: Last Name: DOB: _____ Gender: ID #: Primary Care Physician: Prov. Phone: _____ Prov. Fax: _____ Requesting Provider: Provider Address: Provider NPI: _____ Contact Name: ____ Provider Signature: **Product Information** ☐ New request ☐ Continuation request Drug product: Symdeko 100mg-150mg & 150mg tablet Start date (or date of next dose): Date of last dose (if applicable): Dosing frequency: **Drug cost information**

The wholesale acquisition cost for each Symdeko tablet is \$400.00. The annual cost of treatment with this drug is more than \$288,000.00.

Precertification Requirements

Before this drug is covered, the patient must meet all of the following requirements:

- 1. Must be used for treatment of cystic fibrosis (documentation of a cystic fibrosis ICD10 code* within the last 12 months must be submitted to Priority Health)
- 2. Must be age 6 or older with laboratory confirmation of homozygous F508del mutation in the CFTR (cystic fibrosis transmembrane regulator) gene or CFTR gene mutation responsive to Symdeko.

Note: Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

^{*} Approved ICD10 codes are provided in the Additional Information section



Priority Health Precertification Documentation A. What is the patient's diagnosis? ☐ Cystic fibrosis (documentation of a cystic fibrosis ICD10 code from within the last 12 months)

	submitted to Priority Health) Other: Rationale for use:				
В.	Which of the following m	nutations does the patient h	ave? (please fax labora	tory confirmation)	
	☐ E56K	☐ F1052V	☐ L206W	☐ S1251N	
	☐ A1067T	☐ F1074L	☐ P67L	☐ S1255P	
	☐ A455E	☐ G1069R	☐ R1070Q	☐ S549N	
	☐ D110E	☐ G1244E	☐ R1070W	☐ S549R	
	☐ D110H	☐ G1349D	☐ R117C	☐ S945L	
	☐ D1152H	☐ G178R	☐ R117H	☐ S977F	
	☐ D1270N	☐ G551D	☐ R347H	☐ E831X	
	☐ D579G	☐ G551S	☐ R352Q	☐ 711+3A→G	
	☐ E193K	☐ K1060T	☐ R74W	☐ 2789+5G→A	
	☐ 3272-26A→G	☐ 3849+10kbC→T	☐ F508del*		

Additional Information:

Approved ICD10 Codes for Cystic Fibrosis

ICD10	ICD10 Label			
E84.0	Cystic fibrosis with pulmonary manifestations			
E84.11	Meconium ileus in cystic fibrosis			
E84.19	Cystic fibrosis with other intestinal manifestations			
E84.8	Cystic fibrosis with other manifestations			
E84.9	Cystic fibrosis, unspecified			

^{*}A patient must have two copies of the F508del mutation or at least one copy of a responsive mutation presented in the table above to be indicated.